Triple Incretin Receptor Agonism & Weight Reduction
Retatrutide (LY3437943) — GIP/GLP-1/Glucagon Triple Agonist
Retatrutide (LY3437943, GLP-3 R) is a novel triple agonist developed by Eli Lilly that simultaneously activates three incretin and metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple agonism represents the next generation of metabolic peptide therapeutics, building on the success of GLP-1 agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide).
Phase II clinical trial data published in the New England Journal of Medicine (2023) demonstrated that retatrutide produced up to 24.2% mean body weight reduction at 48 weeks — the largest weight loss observed for any pharmacological agent in a clinical trial to date, surpassing even tirzepatide's results.
Retatrutide is a 37-amino-acid peptide with a fatty acid modification that enables once-weekly subcutaneous dosing through albumin binding. The sequence is based on a glucagon backbone with modifications that enable simultaneous engagement of GIPR, GLP-1R, and GCGR. The molecular weight is 4,731.33 Daltons.
The triple receptor agonism is achieved through careful sequence engineering: the N-terminal region is optimized for GLP-1R and GCGR engagement, while specific residues in the mid-sequence region enable GIPR activation. The fatty acid modification (C18 fatty diacid) enables albumin binding for extended half-life.
Retatrutide's mechanism of action involves simultaneous activation of three receptors with complementary metabolic effects. GLP-1R activation provides glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression. GIPR activation enhances insulin secretion and may contribute to the superior weight loss observed with dual/triple agonists compared to GLP-1R agonists alone.
GCGR activation is the distinguishing feature of retatrutide: glucagon receptor stimulation increases hepatic glucose production (which is counterbalanced by the GLP-1R-mediated insulin secretion), but more importantly, it increases energy expenditure through thermogenic effects in brown adipose tissue and hepatic fatty acid oxidation. This energy expenditure-increasing component may explain the superior weight loss efficacy of retatrutide compared to GLP-1/GIP dual agonists.
GLP-3 R (Retatrutide) is one of the newest and most discussed compounds in metabolic research. It's a triple-receptor agonist — meaning it activates three different hormone receptors simultaneously: GLP-1R, GIP-R, and glucagon receptor. This triple action is what makes it particularly interesting compared to existing GLP-1 drugs like Ozempic, which only target one receptor.
By hitting all three receptors at once, Retatrutide combines the appetite-suppressing, insulin-stimulating effects of GLP-1 with the additional metabolic benefits of GIP (which enhances insulin secretion and may improve GLP-1 receptor sensitivity) and glucagon (which increases energy expenditure and fat burning). In Phase 2 clinical trials published in the New England Journal of Medicine in 2023, Retatrutide produced weight loss of up to 24.2% of body weight over 48 weeks — the highest ever reported for a pharmacological agent in a clinical trial.
The 24% weight loss figure from the Phase 2 trial is genuinely unprecedented in pharmacology. For context, semaglutide (Wegovy) produces about 15% weight loss, and tirzepatide about 20%. Retatrutide's triple-receptor mechanism may represent the next generation of metabolic therapeutics. It's currently in Phase 3 trials, meaning it could reach clinical approval within the next few years.
Retatrutide is arguably the most scientifically exciting compound in this entire catalog right now. Its Phase 2 NEJM data showing 24% weight loss is unprecedented, and its triple-receptor mechanism is at the cutting edge of metabolic research. It is an investigational compound with no current regulatory approval, supplied for laboratory research use only.
Glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression via hypothalamic GLP-1R.
Enhances insulin secretion and may contribute to superior weight loss vs. GLP-1R agonists alone through complementary beta cell effects.
Glucagon receptor activation increases hepatic fatty acid oxidation and brown adipose thermogenesis, raising total energy expenditure.
C18 fatty diacid modification enables reversible albumin binding, extending half-life to support once-weekly dosing.
Metabolic Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Peptide Class | Triple incretin receptor agonist (37 amino acids) |
| Molecular Weight | 4,731.33 Da |
| Receptor Targets | GIPR + GLP-1R + GCGR (triple agonism) |
| Clinical Stage | Phase III (TRIUMPH program, 2025) |
| Peak Weight Loss (Ph. II) | Up to 24.2% at 48 weeks |
| Available Sizes | 5mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers GLP-3 R with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase GLP-3 R at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
